Extendicare (TSE:EXE – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 12th.
Extendicare (TSE:EXE – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported C$0.29 earnings per share for the quarter. Extendicare had a return on equity of 60.00% and a net margin of 4.28%. The company had revenue of C$348.48 million for the quarter, compared to the consensus estimate of C$360.20 million.
Extendicare Stock Performance
Shares of EXE stock opened at C$9.12 on Tuesday. The business’s 50-day moving average price is C$9.10 and its 200-day moving average price is C$8.03. The firm has a market capitalization of C$761.25 million, a price-to-earnings ratio of 13.41 and a beta of 1.26. Extendicare has a 12 month low of C$5.75 and a 12 month high of C$9.52. The company has a current ratio of 0.60, a quick ratio of 0.98 and a debt-to-equity ratio of 305.80.
Extendicare Dividend Announcement
Wall Street Analyst Weigh In
Several research analysts recently issued reports on EXE shares. Royal Bank of Canada raised their target price on Extendicare from C$8.50 to C$9.50 in a research report on Monday, August 19th. TD Securities lifted their price objective on Extendicare from C$9.00 to C$9.50 and gave the stock a “hold” rating in a research note on Wednesday, September 4th.
Check Out Our Latest Research Report on Extendicare
About Extendicare
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties.
Featured Articles
- Five stocks we like better than Extendicare
- 3 REITs to Buy and Hold for the Long Term
- Intel: Is Now the Time to Be Brave?Â
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Buy P&G Now, Before It Sets A New All-Time High
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.